echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Front Immunol: In SARS-CoV-2 infection, excessive activation and consumption of complement can increase hospital mortality!

    Front Immunol: In SARS-CoV-2 infection, excessive activation and consumption of complement can increase hospital mortality!

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Infection-mediated endothelial injury and inflammation have been observed in the blood vessels of various organs of COVID-19 , which may lead to excessive thrombin, trigger thrombus inflammation and ultimately lead to microthrombus deposition and microvascular dysfunction
    .


    In the case of rapid virus replication, T cell lymphatic failure, interferon signaling is suppressed, innate immunity is over-activated , and pro-inflammatory cytokines such as IL-6 and TNFα are produced in large quantities, resulting in immune response disorders and cytokine release syndrome .


    Endothelial injury and inflammation micro thrombus deposition and microvascular dysfunction overactivation of the immune response and cytokine release syndrome disorders Severe

    Purpose: Out -of- control thrombotic inflammation plays an important role in the pathogenesis of coronavirus (COVID-19) caused by SARS-CoV-2 virus
    .


    Complement is considered to be a key factor in this process, so we speculate that the markers of complement system activation may be related to the severity and mortality of COVID-19


    Thrombotic inflammation out of control

    Methods: In this prospective cohort study, samples of 102 hospitalized patients and 26 patients with COVID-19 confirmed by PCR were analyzed
    .


    The main result is COVID-19-related mortality during hospitalization, and the secondary result is the severity of COVID-19 as assessed by the WHO sequential score


    Results: Hospitalized COVID-19 patients have the characteristics of enhanced complement activation
    .


    Complement activation is significantly associated with inflammatory markers such as interleukin-6, C-reactive protein, and ferritin


    Uncontrolled complement activation leads to a higher mortality rate in patients with complement C3 depletion and decreased complement activity than patients with complement activation but not depletion

    Table 1 Correlation between complement parameters and inflammation and fibrinolysis indicators
    .

    Table 1 Correlation between complement parameters and inflammation and fibrinolysis indicators
    .


    Table 2 Univariate and multivariate Cox proportional hazards regression model results analysis of the effect of complement overactivation on hospital mortality; C3a level and C3a/C3 ratio are used as categorical variables,

    Table 2 Univariate and multivariate Cox proportional hazards regression model results analysis of the effect of complement overactivation on hospital mortality; C3a level and C3a/C3 ratio are used as categorical variables,

    Distinguish patients with high or low levels of complement activation (C3a cut-off point is 324 ng/mL, C3a/C3 cut-off point is 200); HR, hazard ratio; CI, confidence interval
    .

    Distinguish patients with high or low levels of complement activation (C3a cut-off point is 324 ng/mL, C3a/C3 cut-off point is 200); HR, hazard ratio; CI, confidence interval
    .


    Conclusion: complement activation and COVID-19 to enhance the progress of the disease related
    .


    When COVID-19 is accompanied by excessive activation and consumption of C3, patients infected with SARS-CoV-2 are more likely to die


    Complement activation and COVID-19 to enhance the progress of the disease related


     Sinkovits G, Mező B, Réti M, et al, Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection.


    Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.